developer_as

About developer_as

This author has not yet filled in any details.
So far developer_as has created 9 blog entries.

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

First project from Arix’s agreement with LDC  LONDON, 20 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds to develop new therapeutics [...]

March 20th, 2017|News Release|

Arix Bioscience plc signs strategic agreement with Takeda

LONDON, 2 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces a strategic agreement with Takeda Ventures, Inc. (“Takeda”). The agreement will maximise the complementary skills and experience of both Arix and Takeda across important therapeutic areas. The relationship brings together [...]

March 20th, 2017|News Release|

ARIX BIOSCIENCE APPOINTS DR FRANZ B HUMER AS SENIOR INDEPENDENT DIRECTOR

LONDON, 31 OCTOBER 2016: Arix Bioscience plc (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it had appointed Dr Franz B Humer as its Senior Independent Director. Dr Humer is one of the pharmaceutical industry’s most respected executives. He served as Chief Executive Officer and Chairman of Hoffmann-La [...]

October 31st, 2016|News Release|

ARIX BIOSCIENCE SUPPORTS ARTIOS PHARMA, A NEW BIOTECH COMPANY FOCUSED ON DNA DAMAGE RESPONSE

LONDON, 21 SEPTEMBER 2016: Arix Bioscience PLC (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has participated, along with leading European and US healthcare investors, in a Series A financing of Artios Pharma Ltd., a new private company focused on the DNA Damage Response (DDR). Artios has [...]

September 21st, 2016|News Release|

ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS

LONDON, JULY 25, 2016: Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has provided equity capital to Depixus, an early-stage company, based in Paris, France that is developing novel technologies for combined genetic and epigenetic analysis. Arix Bioscience sources, finances and develops businesses addressing [...]

July 26th, 2016|News Release|

ARIX BIOSCIENCE SUPPORTS INNOVATIVE RESPIRATORY DRUG COMPANY VERONA PHARMA PLC

Arix Bioscience is pleased to announce that it has participated along with renowned international healthcare investors in a placement with Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases. Verona has announced publicly that it has successfully secured funding commitments to raise gross proceeds of approximately US$63.3 million through [...]

June 20th, 2016|News Release|

ARIX BIOSCIENCE SUPPORTS OPTIKIRA, A COMPANY DEVELOPING DRUGS TO FIGHT BLINDNESS

Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today it has provided development capital to OptiKira, LLC (OptiKira), an early stage company developing drugs to help prevent blindness.

June 13th, 2016|News Release|

ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV

Media Release: Arix Bioscience Limited LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organisation providing access to pioneering science [...]

April 18th, 2016|News Release|

ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS

London, 3 March 2016 – ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS Arix Bioscience, formerly Perceptive Bioscience Investments Ltd, has provided capital support to Autolus Limited (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Alongside Woodford Investment Management LLP, the company has participated in a Series B financing round, providing £40 million of new capital to Autolus. Dr Joe Anderson, CEO of Arix Bioscience, said: ““We are [...]

March 3rd, 2016|News Release, Uncategorised|